EGFR and non-small cell lung carcinoma: In the same population, median PFS was 9.6 months (95% CI: 8.3 to not reached) and the recommended dose for future trials was set at 80 mg/day.7 The subsequent AURA Phase 2 extension study and the open-label Phase 2 AURA2 trial confirmed the safety and efficacy of osimertinib as a post-EGFR-TKI treatment in patients with EGFR-mutated NSCLC with the T790M mutation.8,9